CHMP 建议皮尔法伯实验室批准 OBGEMSA™ (vibegron) 用于治疗膀胱过度活动症。 CHMP recommends approval of OBGEMSA™ (vibegron) for overactive bladder syndrome by Pierre Fabre Laboratories.
皮尔法伯实验室 (Pierre Fabre Laboratories) 获得了 CHMP 对 OBGEMSA™ (vibegron) 治疗膀胱过度活动症 (OAB) 的积极评价。 Pierre Fabre Laboratories received a positive CHMP opinion for OBGEMSA™ (vibegron) in overactive bladder syndrome (OAB). 欧洲药品管理局 CHMP 建议批准 OBGEMSA™ 用于治疗成年 OAB 患者。 The European Medicines Agency's CHMP recommended approval of OBGEMSA™ for treating adult patients with OAB. 皮尔法伯实验室从 Urovant Sciences 获得了独家许可，有权于 2022 年在欧洲经济区注册和商业化 vibegron。 Pierre Fabre Laboratories acquired an exclusive license from Urovant Sciences to register and commercialize vibegron in the European Economic Area in 2022. 欧盟委员会将审查这一决定，并可能授予该药品的上市许可。 The decision will be reviewed by the European Commission, which may grant a marketing authorization for the drug.